DAILY: Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms DAILY
- Sponsors Bayer
- 07 Jun 2017 Biomarkers information updated
- 09 Feb 2017 Status changed from active, no longer recruiting to completed.
- 03 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.